Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
ApexOnco Front Page
Recent articles
21 October 2025
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
20 October 2025
A quartet of failed tiragolumab trials featured at ESMO over the weekend.
20 October 2025
Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.
20 October 2025
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
19 October 2025
Full data from Edge-Gastric are presented at ESMO.
19 October 2025
The first TUB-040 data come just after Tubulis raised €308m.
19 October 2025
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.